The protective effects of long-acting recombinant human pancreatic secretory trypsin inhibitor (R44S-PSTI) in a rat model of cerulein-induced pancreatitis

J Int Med Res. 1996 Jan-Feb;24(1):59-68. doi: 10.1177/030006059602400108.

Abstract

The effects of pancreatic secretory trypsin inhibitor (PSTI) on cerulein-induced pancreatitis were studied in a rat model. Arg44 of PSTI was replaced by Ser using site-directed mutagenesis (R44S-PSTI). R44S-PSTI has a longer half-life than the natural form. Pancreatitis was induced by four intramuscular injections of cerulein (50 microgram/kg at 1 h intervals). Continuous intravenous infusion of R44S-PSTI began at a dose of 20 micrograms/kg/h 30 min before the first cerulein injection, and was completed 3 h after the last cerulein injection. Tumour necrosis factor (TNF-alpha) production by isolated peritoneal macrophages from rats with cerulein-induced pancreatitis increased following lipopolysaccharide stimulation, compared to control rats (P < 0.01). R44S-PSTI administration significantly decreased the TNF-alpha production by peritoneal macrophages from rats with cerulein-induced pancreatitis (P < 0.05). In addition, R44S-PSTI significantly reduced serum amylase activity (P < 0.01) and pancreatic wet weight after pancreatitis induction (P < 0.05). Histological examination revealed marked acinar cell vacuolization, interstitial oedema, and cellular infiltration in cerulein-induced pancreatitis, but a lesser degree of histological change in rats that were treated with R44S-PSTI. Prophylactic use of intravenous R44S-PSTI infusion may reduce the severity of acute pancreatitis either histologically or serologically.

MeSH terms

  • Amylases / blood
  • Animals
  • Ceruletide / toxicity
  • Humans
  • Infusions, Intravenous
  • Lipopolysaccharides / toxicity
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / metabolism
  • Male
  • Mutagenesis, Site-Directed
  • Pancreas / pathology
  • Pancreatitis / chemically induced
  • Pancreatitis / metabolism
  • Pancreatitis / prevention & control*
  • Rats
  • Rats, Wistar
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / genetics
  • Recombinant Proteins / pharmacology
  • Trypsin Inhibitors / administration & dosage
  • Trypsin Inhibitors / genetics
  • Trypsin Inhibitors / pharmacology*
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Lipopolysaccharides
  • Recombinant Proteins
  • Trypsin Inhibitors
  • Tumor Necrosis Factor-alpha
  • Ceruletide
  • Amylases